OVCAR-8
文献支持

OVCAR-8

收藏
  • ¥1800
  • EK-Bioscience已认证
  • CA-Y1731
  • 2025年07月15日
    avatar
    品牌商
    11钻石会员
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • 规格

      T25

    OVCAR-8细胞系 、OVCAR8细胞株  、OVCAR-8  细胞、OVCAR8  细胞、OVCAR-8   卵巢癌细胞

    Cell line name OVCAR-8

    Synonyms OVCAR 8; NIH:OVCAR-8; OVCAR8; Ovcar8; OVCAR.8; OVCA8

    Accession CVCL_1629

    Resource Identification Initiative To cite this cell line use: OVCAR-8 (RRID:CVCL_1629)

    Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

    Part of: COSMIC cell lines project.

    Part of: JFCR39 cancer cell line panel.

    Part of: KuDOS 95 cell line panel.

    Part of: MD Anderson Cell Lines Project.

    Part of: NCI-60 cancer cell line panel.

    Population: Caucasian.

    Doubling time: 24 hours (PubMed=7718330); 25 hours (PubMed=25984343); 26.1 hours (NCI-DTP=OVCAR-8); 31.93 hours (JWGray panel).

    Microsatellite instability: Stable (MSS) (Sanger).

    Omics: Array-based CGH.

    Omics: Chromatin accessibility by ATAC-seq.

    Omics: CNV analysis.

    Omics: CRISPR phenotypic screen.

    Omics: Deep exome analysis.

    Omics: Deep proteome analysis.

    Omics: Deep quantitative proteome analysis.

    Omics: DNA methylation analysis.

    Omics: Fluorescence phenotype profiling.

    Omics: Genome sequenced.

    Omics: lncRNA expression profiling.

    Omics: Metabolome analysis.

    Omics: Protein expression by reverse-phase protein arrays.

    Omics: shRNA library screening.

    Omics: SNP array analysis.

    Omics: Transcriptome analysis by microarray.

    Omics: Transcriptome analysis by RNAseq.

    Misspelling: OVACAR8; Cosmic=1526923.

    Misspelling: OVOCAR-8; Note=Occasionally.

    Misspelling: OVOCAR8; Note=Occasionally.

    PubMed=10700174; DOI=10.1038/73432

    Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

    Systematic variation in gene expression patterns in human cancer cell lines.

    Nat. Genet. 24:227-235(2000)

     

    PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x; PMCID=PMC5926887

    Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M., Takayama M., Sato A., Inazawa J.

    Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.

    Jpn. J. Cancer Res. 93:1114-1122(2002)

     

    PubMed=12960427; DOI=10.1091/mbc.E03-05-0279; PMCID=PMC266758

    Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O.G., Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H., Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J., Kristensen G.B., Borresen-Dale A.-L., Hastie T., Tibshirani R., van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O., Sikic B.I.

    Gene expression patterns in ovarian carcinomas.

    Mol. Biol. Cell 14:4376-4386(2003)

     

    PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742

    Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M.

    HLA class I and II genotype of the NCI-60 cell lines.

    J. Transl. Med. 3:11.1-11.8(2005)

     

    PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832

    Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., MiroT., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

    Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

    Mol. Cancer Ther. 5:2606-2612(2006)

     

    PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356

    Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.

    DNA fingerprinting of the NCI-60 cell line panel.

    Mol. Cancer Ther. 8:713-724(2009)

     

    PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

    Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

    Signatures of mutation and selection in the cancer genome.

    Nature 463:893-898(2010)

     

    PubMed=20204287; DOI=10.3892/or_00000728; PMCID=PMC2909445

    Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H., Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.

    Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.

    Oncol. Rep. 23:1021-1026(2010)

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献

    *发表【中文论文】请标注:由上海酶研生物科技有限公司提供;

    *发表【英文论文】请标注:From Shanghai EK-Bioscience Biotechnology Co., Ltd.

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥1400
    上海盖宁生物科技有限公司
    2025年12月10日询价
    ¥900
    安元生物科技(南京)有限公司
    2025年07月16日询价
    ¥1300
    上海匹拓生物科技有限公司
    2025年12月16日询价
    ¥1800
    上海酶研生物科技有限公司
    2025年07月12日询价
    ¥1620
    博辉生物科技(广州)有限公司
    2025年12月05日询价
    文献支持
    OVCAR-8
    ¥1800